Logo Logo
Hilfe
Hilfe
Switch Language to English

Bodensohn, Raphael; Kaempfel, Anna-Lena; Fleischmann, Daniel Felix; Hadi, Indrawati; Hofmaier, Jan; Garny, Sylvia; Reiner, Michael; Forbrig, Robert; Corradini, Stefanie; Thon, Niklas; Belka, Claus ORCID logoORCID: https://orcid.org/0000-0002-1287-7825 und Niyazi, Maximilian (2021): Simultaneous stereotactic radiosurgery of multiple brain metastases using single-isocenter dynamic conformal arc therapy: a prospective monocentric registry trial. In: Strahlentherapie und Onkologie, Bd. 197, Nr. 7: S. 601-613 [PDF, 434kB]

Abstract

BACKGROUND Single-isocenter dynamic conformal arc (SIDCA) therapy is a~technically efficient way of delivering stereotactic radiosurgery (SRS) to multiple metastases simultaneously. This study reports on the safety and feasibility of linear accelerator (LINAC) based SRS with SIDCA for patients with multiple brain metastases. METHODS All patients who received SRS with this technique between November 2017 and June 2019 within a~prospective registry trial were included. The patients were irradiated with a~dedicated planning tool for multiple brain metastases using a~LINAC with a~5 mm multileaf collimator. Follow-up was performed every 3~months, including clinical and radiological examination with cranial magnetic resonance imaging (MRI). These early data were analyzed using descriptive statistics and the Kaplan-Meier method. RESULTS A total of 65~patients with 254 lesions (range 2-12) were included in this analysis. Median beam-on time was 23 min. The median follow-up at the time of analysis was 13~months (95% CI 11.1-14.9). Median overall survival and median intracranial progression-free survival was 15~months (95% CI 7.7-22.3) and 7~months (95% CI 3.9-10.0), respectively. Intracranial and local control after 1~year was 64.6~and 97.5%, respectively. During follow-up, CTCAE grade~I adverse effects (AE) were experienced by 29~patients (44.6%; 18~of them therapy related, 27.7%), CTCAE grade~II~AEs by four patients (6.2%; one of them therapy related, 1.5%), and CTCAE grade~III~by three patients (4.6%; none of them therapy related). Two lesions (0.8%) in two patients (3.1%) were histopathologically proven to be radiation necrosis. CONCLUSION Simultaneous SRS using SIDCA seems to be a~feasible and safe treatment for patients with multiple brain metastases.

Dokument bearbeiten Dokument bearbeiten